@article{a551408e19cf462c8613236ca9ace1e6,
title = "Understanding and preventing type 1 diabetes through the unique working model of TrialNet",
abstract = "Type 1 diabetes is an autoimmune disease arising from the destruction of pancreatic insulin-producing beta cells. The disease represents a continuum, progressing sequentially at variable rates through identifiable stages prior to the onset of symptoms, through diagnosis and into the critical periods that follow, culminating in a variable depth of beta cell depletion. The ability to identify the very earliest of these presymptomatic stages has provided a setting in which prevention strategies can be trialled, as well as furnishing an unprecedented opportunity to study disease evolution, including intrinsic and extrinsic initiators and drivers. This niche opportunity is occupied by Type 1 Diabetes TrialNet, an international consortium of clinical trial centres that leads the field in intervention and prevention studies, accompanied by deep longitudinal bio-sampling. In this review, we focus on discoveries arising from this unique bioresource, comprising more than 70,000 samples, and outline the processes and science that have led to new biomarkers and mechanistic insights, as well as identifying new challenges and opportunities. We conclude that via integration of clinical trials and mechanistic studies, drawing in clinicians and scientists and developing partnership with industry, TrialNet embodies an enviable and unique working model for understanding a disease that to date has no cure and for designing new therapeutic approaches.",
keywords = "Autoimmunity, Mechanistic studies, Review, Type 1 diabetes",
author = "Manuela Battaglia and Anderson, {Mark S.} and Buckner, {Jane H.} and Geyer, {Susan M.} and Gottlieb, {Peter A.} and Kay, {Thomas W.H.} and {\AA}ke Lernmark and Sarah Muller and Alberto Pugliese and Roep, {Bart O.} and Greenbaum, {Carla J.} and Mark Peakman",
note = "Funding Information: Duality of interest MSA owns stocks of Medtronic. {\AA}L is a member of the Scientific Advisory Board of Diamyd Medical, Stockholm, Sweden. CJG is a consultant for Bristol-Myers Squibb and receives research funding from Janssen. All other authors declare that there is no duality of interest associated with their contributions to this manuscript. Funding Information: Funding The sponsor of the trial was the Type 1 Diabetes TrialNet Study Group. Type 1 Diabetes TrialNet Study Group is a clinical trials network funded by the National Institutes of Health (NIH) through the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Allergy and Infectious Diseases and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (through the cooperative agreements U01 DK061010, U01 DK061034, U01 DK061042, U01 DK061058, U01 DK085465, U01 DK085453, U01 DK085461, U01 DK085466, U01 DK085499, U01 DK085504, U01 DK085509, U01 DK103180, U01 DK103153, U01 DK085476, U01 DK103266, U01 DK103282, U01 DK106984, U01 DK106994, U01 DK107013, U01 DK107014, UC4 DK106993) and JDRF. The content of this review is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or JDRF. Publisher Copyright: {\textcopyright} 2017, The Author(s).",
year = "2017",
month = nov,
day = "1",
doi = "10.1007/s00125-017-4384-2",
language = "English (US)",
volume = "60",
pages = "2139--2147",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "11",
}